StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$5.10−0.12 (-2.30%)

Close on Nov 17, 2026Market cap $234.07MP/E –Yield –

Earnings

BioAge Labs's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 23, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$300.00K
-85.7% on a year earlier
EPS, Q3 FY2026
-$0.73
-$0.56 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BioAge Labs's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$300.00K-85.7%-$0.73Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$2.40M-0.5%-$0.58Release
Q1 FY2026ended Mar 31, 2026May 8, 2026before the open$2.80M–-$0.52Release
Q4 FY2025ended Dec 31, 2025Mar 24, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$2.10M–-$0.56Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$2.41M–-$0.60Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 20, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close––-$6.70Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BioAge Labs has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BioAge Labs puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BioAge Labs filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?